Histoplasmosis - 30/01/25
Doi : 10.1016/j.idc.2024.11.009
Emily M. Eichenberger, MD, MHS a, ⁎ 
, Jessica S. Little, MD b, c, John W. Baddley, MD, MSPH d, e
, Jessica S. Little, MD b, c, John W. Baddley, MD, MSPH d, e a Division of Infectious Disease, Department of Medicine, Emory School of Medicine, Atlanta, GA, USA
b Division of Infectious Disease, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, PBB-A4, Boston, MA 02115, USA
c Division of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
d Division of Infectious Disease, Department of Medicine, Johns Hopkins University School of Medicine, Boston, MA, USA
e Division of Infectious Diseases, Transplant and Oncology Infectious Diseases, The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA
∗Corresponding author. 101 Woodruff Circle, WMB, Suite 5125, Atlanta, GA 30322.101 Woodruff Circle, WMBSuite 5125AtlantaGA30322
Résumé |
This review provides an update of histoplasmosis, covering the changing epidemiology, pathogenesis, disease manifestations, diagnostic strategies, and management considerations for immunocompetent and immunocompromised populations.
Le texte complet de cet article est disponible en PDF.Keywords : Histoplasmosis, Histoplasma capsulatum, Endemic mycosis, Dimorphic fungi, Itraconazole
Plan
© 2024
Elsevier Inc. Tous droits réservés.
Vol 39 - N° 1
P. 145-161 - mars 2025 Retour au numéro
Article précédent
- Mucormycosis
- Mary M. Czech, Jennifer Cuellar-Rodriguez
- Blastomycosis
- Shiwei Zhou, Carol A. Kauffman, Marisa H. Miceli
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?